T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Cullinan Oncology
CGEM
$1.29B
| $151K | ﹤0.01% |
11,746
+619
| +6% | +$7.02K |
|
2652
McEwen Inc
MUX
$1.13B
| $151K | ﹤0.01% |
34,280
+11,260
| +49% | +$70.1K |
|
|
PW
2653
Power REIT
PW
$2.9M
| $151K | ﹤0.01% |
1,186
+70
| +6% | +$17K |
|
|
FFAI
2654
Faraday Future Intelligent Electric
FFAI
$11.6M
| – | – |
0
| – | – |
|
|
VBIV
2655
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $151K | ﹤0.01% |
6,244
+1,724
| +38% | +$58.7K |
|
2656
Vertex
VERX
$2.02B
| $150K | ﹤0.01% |
13,200
| – | – |
|
|
TSP
2657
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
| $150K | ﹤0.01% |
20,749
+5,666
| +38% | +$51.5K |
|
2658
Axogen
AXGN
$2.58B
| $149K | ﹤0.01% |
18,229
-334
| -2% | -$2.85K |
|
2659
Crescent Energy
CRGY
$3.93B
| $148K | ﹤0.01% |
11,830
-2,009
| -15% | -$33.5K |
|
2660
Corsair Gaming
CRSR
$1.47B
| $148K | ﹤0.01% |
+11,257
| New | +$184K |
|
2661
Lipocine
LPCN
$17.3M
| $148K | ﹤0.01% |
10,862
| – | – |
|
2662
Precigen
PGEN
$2.32B
| $148K | ﹤0.01% |
110,624
+36,358
| +49% | +$53.9K |
|
2663
Fulcrum Therapeutics
FULC
$283M
| $146K | ﹤0.01% |
29,717
+4,512
| +18% | +$44.1K |
|
2664
Vital Farms
VITL
$499M
| $146K | ﹤0.01% |
16,707
+4,339
| +35% | +$46.2K |
|
2665
Aemetis
AMTX
$127M
| $145K | ﹤0.01% |
29,507
-8,479
| -22% | -$74.1K |
|
|
ONL
2666
Orion Office REIT
ONL
$159M
| $145K | ﹤0.01% |
13,255
+2,179
| +20% | +$28.1K |
|
|
CSSE
2667
DELISTED
Chicken Soup for the Soul Entertainment, Inc. Class A Common Stock
CSSE
| $144K | ﹤0.01% |
19,500
-744
| -4% | -$5.7K |
|
|
YELL
2668
DELISTED
Yellow Corporation Common Stock
YELL
| $144K | ﹤0.01% |
49,243
-4,537
| -8% | -$18.4K |
|
2669
GoodRx Holdings
GDRX
$1.23B
| $143K | ﹤0.01% |
24,100
+9,500
| +65% | +$106K |
|
2670
Noodles & Co
NDLS
$101M
| $142K | ﹤0.01% |
3,774
+756
| +25% | +$33.6K |
|
|
ENG
2671
DELISTED
ENGlobal Corp
ENG
| $142K | ﹤0.01% |
18,677
-562
| -3% | -$5.12K |
|
2672
Liquidity Services
LQDT
$1.33B
| $141K | ﹤0.01% |
+10,479
| New | +$154K |
|
|
DSKE
2673
DELISTED
Daseke, Inc. Common Stock
DSKE
| $141K | ﹤0.01% |
+22,040
| New | +$168K |
|
2674
CareCloud
CCLD
$104M
| $140K | ﹤0.01% |
40,800
+2,300
| +6% | +$9.12K |
|
2675
PharmaCyte Biotech
PMCB
$6M
| $140K | ﹤0.01% |
62,000
-16,100
| -21% | -$35.2K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.